

What is claimed is:

1. An isolated polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide having a sequence chosen from: **SEQ ID NOS: 2, 4, 6, 8, 10, 14, 16, 55 to 75, 77 to 79, 81, 83** or fragments, analogs or derivatives thereof.
2. A polynucleotide according to claim 1, wherein said polynucleotide encodes a polypeptide having at least 95% identity to the second polypeptide.
3. An isolated polynucleotide encoding a polypeptide capable of generating antibodies having binding specificity for a polypeptide having a sequence chosen from: **SEQ ID NOS: 2, 4, 6, 8, 10, 14, 16, 55 to 75, 77 to 79, 81, 83** or fragments, analogs or derivatives thereof.
4. An isolated polynucleotide that is complementary to the polynucleotide of claim 1.
5. An isolated polynucleotide that is complementary to the polynucleotide of claim 3.
6. The polynucleotide of claim 1, wherein said polynucleotide is DNA.
7. The polynucleotide of claim 3, wherein said polynucleotide is DNA.
8. The polynucleotide of claim 1, wherein said polynucleotide is RNA.

9. The polynucleotide of claim 3, wherein said polynucleotide is RNA.

10. A vector comprising the polynucleotide of claim 1, wherein said DNA is operably linked to an expression control region.

11. A vector comprising the polynucleotide of claim 3, wherein said DNA is operably linked to an expression control region.

12. A host cell transfected with the vector of claim 10.

13. A host cell transfected with the vector of claim 11.

14. A process for producing a polypeptide comprising culturing a host cell according to claim 12 under conditions suitable for expression of said polypeptide.

15. A process for producing a polypeptide comprising culturing a host cell according to claim 13 under condition suitable for expression of said polypeptide.

16. An isolated polypeptide having at least 70% identity to a second polypeptide having an amino acid sequence chosen from: SEQ ID NOS: 2, 4, 6, 8, 10, 14, 16, 55 to 75, 77 to 79, 81, 83 or fragments, analogs or derivatives thereof.

17. An isolated polypeptide capable of generating antibodies having binding specificity for a second polypeptide

having a sequence chosen from: SEQ ID NOS: 2, 4, 6, 8, 10, 14, 16, 55 to 75, 77 to 79, 81, 83 or fragments, analogs or derivatives thereof.

*Sub 5*

18. An isolated polypeptide having an amino acid sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10, 14, 16, 55 to 75, 77 to 79, 81, 83 or fragments, analogs or derivatives thereof.

19. An isolated polypeptide according to claim 18, wherein the N-terminal Met residue is deleted.

20. An isolated polypeptide according to claim 18, wherein the secretory amino acid sequence is deleted.

21. A chimeric polypeptide comprising two or more polypeptides chosen from SEQ ID NOS: 2, 4, 6, 8, 10, 14, 16, 55 to 75, 77 to 79, 81, 83 or fragments, analogs or derivatives thereof; provided that the polypeptides or fragments, analogs or derivatives thereof are linked as to form a chimeric polypeptide.

22. A chimeric polypeptide comprising two or more polypeptides chosen from SEQ ID NOS :10, 58, 60, 62, 64, 67, 68, 69, 72, 74, 77 or fragments, analogs or derivatives thereof; provided that the polypeptides or fragments, analogs or derivatives thereof are linked as to form a chimeric polypeptide.

23. A chimeric polypeptide of formula (I):

$A - (B)_m - (C)_n - D$  (I)

Wherein;

**m** is 0 or 1,  
**n** is 0 or 1,  
**A** is chosen from SEQ ID NOS: 2, 4, 6, 8, 10, 14, 16, 55  
to 75, 77 to 79, 81, 83 or fragments, analogs or  
derivatives thereof;  
**B** is chosen from SEQ ID NOS: 2, 4, 6, 8, 10, 14, 16, 55  
to 75, 77 to 79, 81, 83 or fragments, analogs or  
derivatives thereof;  
**C** is chosen from SEQ ID NOS: 2, 4, 6, 8, 10, 14, 16, 55  
to 75, 77 to 79, 81, 83 or fragments, analogs or  
derivatives thereof; and  
**D** is chosen from SEQ ID NOS: 2, 4, 6, 8, 10, 14, 16, 55  
to 75, 77 to 79, 81, 83 or fragments, analogs or  
derivatives thereof.

24. A chimeric polypeptide of formula (I):

**A**-**(B)**<sub>**m**</sub>-**(C)**<sub>**n**</sub>-**D** (I)

Wherein;

**m** is 0 or 1,

**n** is 0 or 1,

**A** is chosen from SEQ ID NOS :10, 58, 60, 62, 64, 67, 68,  
69, 72, 74, 77 or fragments, analogs or derivatives  
thereof;

**B** is chosen from SEQ ID NOS :10, 58, 60, 62, 64, 67, 68,  
69, 72, 74, 77, or fragments, analogs or derivatives  
thereof;

**C** is chosen from SEQ ID NOS :10, 58, 60, 62, 64, 67, 68,  
69, 72, 74, 77 or fragments, analogs or derivatives  
thereof; and

**D** is chosen from SEQ ID NOS :10, 58, 60, 62, 64, 67, 68,  
69, 72, 74, 77 or fragments, analogs or derivatives  
thereof.

*Subj*

25. A vaccine composition comprising a polypeptide according to any one of claims 16 to 24 and a pharmaceutically acceptable carrier, diluent or adjuvant.

26. A method for therapeutic or prophylactic treatment of meningitis, otitis media, bacteremia or pneumonia infection in an individual susceptible to meningitis, otitis media, bacteremia or pneumonia infection comprising administering to said individual a therapeutic or prophylactic amount of a composition according to claim 25.

27. A method for therapeutic or prophylactic treatment of streptococcal bacterial infection in an individual susceptible to streptococcal infection comprising administering to said individual a therapeutic or prophylactic amount of a composition according to claim 25.

28. A method according to claim 26, wherein said individual is a mammal.

29. A method according to claim 27, wherein said individual is a human.

30. A method according to claim 22, wherein said bacterial infection is S.pneumoniae, group A *streptococcus* (*pyogenes*), group B *streptococcus* (GBS or *agalactiae*), *dysgalactiae*, *uberis*, *nocardia* or *Staphylococcus aureus*.

*Orb C*

31. A method according to claim 26, wherein said bacterial infection is S.pneumoniae.

add  
V2  
add  
E5